157 related articles for article (PubMed ID: 17283445)
1. Reliable generation of stable high titer producer cell lines for gene therapy.
Rattmann I; Kleff V; Feldmann A; Ludwig C; Sorg UR; Opalka B; Moritz T; Flasshove M
Intervirology; 2007; 50(3):197-203. PubMed ID: 17283445
[TBL] [Abstract][Full Text] [Related]
2. An improved method for generating retroviral producer clones for vectors lacking a selectable marker gene.
Persons DA; Mehaffey MG; Kaleko M; Nienhuis AW; Vanin EF
Blood Cells Mol Dis; 1998 Jun; 24(2):167-82. PubMed ID: 9642098
[TBL] [Abstract][Full Text] [Related]
3. A comparative evaluation of gene transfer into blood cells using the same retroviral backbone for independent expression of the EGFP and deltaLNGFR marker genes.
Giaretta I; Madeo D; Bonaguro R; Cappellari A; Rodeghiero F; Giorgio P
Haematologica; 2000 Jul; 85(7):680-9. PubMed ID: 10897118
[TBL] [Abstract][Full Text] [Related]
4. Generation of a conditionally neo(r)-containing retroviral producer cell line: effects of neo(r) on retroviral titer and transgene expression.
Wildner O; Candotti F; Krecko EG; Xanthopoulos KG; Ramsey WJ; Blaese RM
Gene Ther; 1998 May; 5(5):684-91. PubMed ID: 9797874
[TBL] [Abstract][Full Text] [Related]
5. The use of recombinase mediated cassette exchange in retroviral vector producer cell lines: predictability and efficiency by transgene exchange.
Coroadinha AS; Schucht R; Gama-Norton L; Wirth D; Hauser H; Carrondo MJ
J Biotechnol; 2006 Jul; 124(2):457-68. PubMed ID: 16529836
[TBL] [Abstract][Full Text] [Related]
6. Construction of a high efficiency retroviral vector for gene therapy of Hunter's syndrome.
Hong Y; Yu SS; Kim JM; Lee K; Na YS; Whitley CB; Sugimoto Y; Kim S
J Gene Med; 2003 Jan; 5(1):18-29. PubMed ID: 12516048
[TBL] [Abstract][Full Text] [Related]
7. Stable in vivo gene transduction via a novel adenoviral/retroviral chimeric vector.
Feng M; Jackson WH; Goldman CK; Rancourt C; Wang M; Dusing SK; Siegal G; Curiel DT
Nat Biotechnol; 1997 Sep; 15(9):866-70. PubMed ID: 9306401
[TBL] [Abstract][Full Text] [Related]
8. A convenient method for positive selection of retroviral producing cells generating vectors devoid of selectable markers.
Xu L; Tsuji K; Mostowski H; Otsu M; Candotti F; Rosenberg AS
J Virol Methods; 2004 Jun; 118(1):61-7. PubMed ID: 15158069
[TBL] [Abstract][Full Text] [Related]
9. Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles.
Reuss S; Biese P; Cosset FL; Takeuchi Y; Uckert W
Gene Ther; 2007 Apr; 14(7):595-603. PubMed ID: 17235289
[TBL] [Abstract][Full Text] [Related]
10. Large-scale manufacturing of safe and efficient retrovirus packaging lines for use in immunotherapy protocols.
Farson D; McGuinness R; Dull T; Limoli K; Lazar R; Jalali S; Reddy S; Pennathur-Das R; Broad D; Finer M
J Gene Med; 1999; 1(3):195-209. PubMed ID: 10738568
[TBL] [Abstract][Full Text] [Related]
11. Green fluorescent protein as a selectable marker of retrovirally transduced hematopoietic progenitors.
Kume A; Hashiyama M; Suda T; Ozawa K
Stem Cells; 1999; 17(4):226-32. PubMed ID: 10437986
[TBL] [Abstract][Full Text] [Related]
12. Construction of new retroviral producer cells from adenoviral and retroviral vectors.
Lin X
Gene Ther; 1998 Sep; 5(9):1251-8. PubMed ID: 9930327
[TBL] [Abstract][Full Text] [Related]
13. Optimization of retroviral vector generation for clinical application.
Schilz AJ; Kühlcke K; Fauser AA; Eckert HG
J Gene Med; 2001; 3(5):427-36. PubMed ID: 11601756
[TBL] [Abstract][Full Text] [Related]
14. [Sorting of packaging cells for retroviral vector carrying green fluorescent gene and viral titer determination].
Zhang YG; Guo X; Zhou JJ; Yu B; Liu B
Di Yi Jun Yi Da Xue Xue Bao; 2005 Jan; 25(1):30-2, 36. PubMed ID: 15683992
[TBL] [Abstract][Full Text] [Related]
15. A new generation of retroviral producer cells: predictable and stable virus production by Flp-mediated site-specific integration of retroviral vectors.
Schucht R; Coroadinha AS; Zanta-Boussif MA; Verhoeyen E; Carrondo MJ; Hauser H; Wirth D
Mol Ther; 2006 Aug; 14(2):285-92. PubMed ID: 16697259
[TBL] [Abstract][Full Text] [Related]
16. [In vitro study on transduction of human O(6)-methylguanine-DNA-methyltransferase cDNA into human umbilical cord blood CD34(+) cells].
Wang J; Xia X; Chen Z; Lu D; Xue J; Ruan C
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2000 Dec; 17(6):395-8. PubMed ID: 11110975
[TBL] [Abstract][Full Text] [Related]
17. Sorting vector producer cells for high transgene expression increases retroviral titer.
Beaudoin EL; Bais AJ; Junghans RP
J Virol Methods; 2008 Mar; 148(1-2):253-9. PubMed ID: 18249448
[TBL] [Abstract][Full Text] [Related]
18. Generation of a high-titer packaging cell line for the production of retroviral vectors in suspension and serum-free media.
Ghani K; Cottin S; Kamen A; Caruso M
Gene Ther; 2007 Dec; 14(24):1705-11. PubMed ID: 17928873
[TBL] [Abstract][Full Text] [Related]
19. Retroviral end-point titer is not predictive of gene transfer efficiency: implications for vector production.
Forestell SP; Böhnlein E; Rigg RJ
Gene Ther; 1995 Dec; 2(10):723-30. PubMed ID: 8750011
[TBL] [Abstract][Full Text] [Related]
20. Equal potency of gammaretroviral and lentiviral SIN vectors for expression of O6-methylguanine-DNA methyltransferase in hematopoietic cells.
Schambach A; Bohne J; Chandra S; Will E; Margison GP; Williams DA; Baum C
Mol Ther; 2006 Feb; 13(2):391-400. PubMed ID: 16226060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
